Recent Finacing
Recent Raise
Mysthera Therapeutics develops oral pan‑PIM kinase inhibitors—in‑licensed from Inflection Biosciences—to selectively modulate multi‑lineage immune cell function for treatment of complex autoimmune diseases.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor